Publikation:

PU.1 supports TRAIL-induced cell death by inhibiting NF-κB-mediated cell survival and inducing DR5 expression

Vorschaubild

Dateien

Haimovici_2-1rkme4vi4126k0.pdf
Haimovici_2-1rkme4vi4126k0.pdfGröße: 397.55 KBDownloads: 189

Datum

2017

Autor:innen

Haimovici, Aladin
Humbert, Magali
Federzoni, Elena A
Shan-Krauer, Deborah
Frese, Steffen
Kaufmann, Thomas
Torbett, Bruce E
Tschan, Mario P.

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

URI (zitierfähiger Link)
http://nbn-resolving.de/urn:nbn:de:bsz:352-2-1rkme4vi4126k0
DOI (zitierfähiger Link)
https://doi.org/10.1038/cdd.2017.40
ArXiv-ID

Internationale Patentnummer

Link zur Lizenz
Urheberrechtlich geschützt

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung
Open Access Green

Sammlungen

Biologie: Publikationen
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Cell Death and Differentiation. 2017, 24(5), pp. 866-877. ISSN 1350-9047. eISSN 1476-5403. Available under: doi: 10.1038/cdd.2017.40

Zusammenfassung

The hematopoietic Ets-domain transcription factor PU.1/SPI1 orchestrates myeloid, B- and T-cell development, and also supports hematopoietic stem cell maintenance. Although PU.1 is a renowned tumor suppressor in acute myeloid leukemia (AML), a disease characterized by an accumulation of immature blast cells, comprehensive studies analyzing the role of PU.1 during cell death responses in AML treatment are missing. Modulating PU.1 expression in AML cells, we found that PU.1 supports tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis via two mechanisms: (a) by repressing NF-κB activity via a novel direct PU.1-RelA/p65 protein-protein interaction, and (b) by directly inducing TRAIL receptor DR5 expression. Thus, expression of NF-κB-regulated antiapoptotic genes was sustained in PU.1-depleted AML cells upon TRAIL treatment and DR5 levels were decreased. Last, PU.1 deficiency significantly increased AML cell resistance to anthracycline treatment. Altogether, these results reveal a new facet of PU.1's tumor suppressor function during antileukemic therapies.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690HAIMOVICI, Aladin, Magali HUMBERT, Elena A FEDERZONI, Deborah SHAN-KRAUER, Thomas BRUNNER, Steffen FRESE, Thomas KAUFMANN, Bruce E TORBETT, Mario P. TSCHAN, 2017. PU.1 supports TRAIL-induced cell death by inhibiting NF-κB-mediated cell survival and inducing DR5 expression. In: Cell Death and Differentiation. 2017, 24(5), pp. 866-877. ISSN 1350-9047. eISSN 1476-5403. Available under: doi: 10.1038/cdd.2017.40
BibTex
@article{Haimovici2017suppo-39222,
  year={2017},
  doi={10.1038/cdd.2017.40},
  title={PU.1 supports TRAIL-induced cell death by inhibiting NF-κB-mediated cell survival and inducing DR5 expression},
  number={5},
  volume={24},
  issn={1350-9047},
  journal={Cell Death and Differentiation},
  pages={866--877},
  author={Haimovici, Aladin and Humbert, Magali and Federzoni, Elena A and Shan-Krauer, Deborah and Brunner, Thomas and Frese, Steffen and Kaufmann, Thomas and Torbett, Bruce E and Tschan, Mario P.}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/39222">
    <dc:contributor>Humbert, Magali</dc:contributor>
    <dc:contributor>Frese, Steffen</dc:contributor>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/39222/1/Haimovici_2-1rkme4vi4126k0.pdf"/>
    <dc:contributor>Haimovici, Aladin</dc:contributor>
    <dc:creator>Humbert, Magali</dc:creator>
    <dcterms:abstract xml:lang="eng">The hematopoietic Ets-domain transcription factor PU.1/SPI1 orchestrates myeloid, B- and T-cell development, and also supports hematopoietic stem cell maintenance. Although PU.1 is a renowned tumor suppressor in acute myeloid leukemia (AML), a disease characterized by an accumulation of immature blast cells, comprehensive studies analyzing the role of PU.1 during cell death responses in AML treatment are missing. Modulating PU.1 expression in AML cells, we found that PU.1 supports tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis via two mechanisms: (a) by repressing NF-κB activity via a novel direct PU.1-RelA/p65 protein-protein interaction, and (b) by directly inducing TRAIL receptor DR5 expression. Thus, expression of NF-κB-regulated antiapoptotic genes was sustained in PU.1-depleted AML cells upon TRAIL treatment and DR5 levels were decreased. Last, PU.1 deficiency significantly increased AML cell resistance to anthracycline treatment. Altogether, these results reveal a new facet of PU.1's tumor suppressor function during antileukemic therapies.</dcterms:abstract>
    <dc:creator>Federzoni, Elena A</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:issued>2017</dcterms:issued>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/39222"/>
    <dc:language>eng</dc:language>
    <dc:creator>Brunner, Thomas</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Shan-Krauer, Deborah</dc:creator>
    <dc:contributor>Kaufmann, Thomas</dc:contributor>
    <dc:contributor>Brunner, Thomas</dc:contributor>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/39222/1/Haimovici_2-1rkme4vi4126k0.pdf"/>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:contributor>Tschan, Mario P.</dc:contributor>
    <dc:contributor>Shan-Krauer, Deborah</dc:contributor>
    <dc:creator>Haimovici, Aladin</dc:creator>
    <dc:creator>Tschan, Mario P.</dc:creator>
    <dc:contributor>Federzoni, Elena A</dc:contributor>
    <dc:contributor>Torbett, Bruce E</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-06-13T07:31:57Z</dc:date>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Frese, Steffen</dc:creator>
    <dc:creator>Torbett, Bruce E</dc:creator>
    <dc:rights>terms-of-use</dc:rights>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dcterms:title>PU.1 supports TRAIL-induced cell death by inhibiting NF-κB-mediated cell survival and inducing DR5 expression</dcterms:title>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-06-13T07:31:57Z</dcterms:available>
    <dc:creator>Kaufmann, Thomas</dc:creator>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Diese Publikation teilen